TREATMENT MODALITY OF CHRONIC POLYPOID RHINOSINUSITIS IN PATIENTS WITH ASPIRIN TRIAD

摘要

The invention relates to medicine, namely to otorhinolaryngology, allergology and pulmonology, and is intended for treatment of chronic polypoid rhinosinusitis in patients with aspirin (asthmatic) triad during their post-surgical period. The goal of the declared modality is to increase the effectiveness of treatment by reducing the risk of side effects induced by non-steroid anti-inflammation medications. The essence of the invention is as follows. Following surgical treatment, endonasal mometasone furoate therapy is conducted of paranasal sinuses administering a dose of 100 μg twice a day for a month; next, ketorolac is administered endonasally to the amount of 1.26 mg per dose, 2 – 4 doses per day up each nasal passage for at least two years.